Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer

Publication Date

2020

Journal Title

Future Oncol

Volume Number

16

Issue Number

1

Pages

4289 - 4301

Document Type

Article

Status

Faculty

Facility

School of Medicine

Primary Department

Hematology/Medical Oncology

PMID

31778074

DOI

10.2217/fon-2019-0653

Comments

Hofstra Northwell School of Medicine and Northwell Health currently do not subscribe to this title. If you are an affiliate and would like to access the full text please request it via interlibrary loan via Hofstra Northwell School of Medicine ILL (faculty and students only) or Northwell Health ILL

This document is currently not available here.


Share

COinS